Research cycle | Screening period | Baseline period | Treatment period | Early termination | Follow-up period | |||||
---|---|---|---|---|---|---|---|---|---|---|
Time point | Week 1 | Week 0 | Week 1 | Week 2 | Week 3 | Week 4 | Week 6 | Week 8 | ||
Enrollment | Inclusion/exclusion criteria | ● | ● | |||||||
Informed consent | ● | |||||||||
Demographic characteristics | ● | |||||||||
Medical history | ● | |||||||||
Registration | ● | |||||||||
Randomization | ● | |||||||||
Photographs of skin lesions | ● | ● | ● | ● | ● | ● | ● | ● | ||
Interventions | Basic therapy + fire needle therapy | ★-------------------------------------------------------------------★ | ||||||||
Basic therapy + fire needle control therapy | ☆-------------------------------------------------------------------☆ | |||||||||
Assessment | PASI | ● | ● | ● | ● | ● | ● | ● | ● | ● |
BSA | ● | ● | ● | ● | ● | ● | ● | ● | ● | |
PGA | ● | ● | ● | ● | ● | ● | ● | ● | ● | |
DLQI | ● | ● | ● | ● | ● | ● | ||||
PRQoL | ● | ● | ● | ● | ● | ● | ||||
VAS | ● | ● | ● | ● | ● | ● | ● | ● | ||
TCM symptom | ● | ● | ● | ● | ● | ● | ||||
Recurrence rate | ● | ● | ||||||||
Safety | Vital signs | ● | ● | ● | ● | ● | ● | ● | ● | ● |
Blood routine | ● | ● | ● | |||||||
Blood biochemistry | ● | ● | ● | |||||||
Urine routine | ● | ● | ● | |||||||
Concomitant medication | ● | ● | ● | ● | ● | ● | ● | |||
Pregnancy test | ● | |||||||||
Physical examination | ● | ● | ● | ● | ● | |||||
Adverse events | ● | ● | ● | ● | ● | ● | ● | ● | ||
Serious adverse events | ● | ● | ● | ● | ● | ● | ● | ● | ● |